Bridgeway Capital Management, LLC Design Therapeutics, Inc. Transaction History
Bridgeway Capital Management, LLC
- $3.98 Billion
- Q2 2025
A detailed history of Bridgeway Capital Management, LLC transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Bridgeway Capital Management, LLC holds 188,200 shares of DSGN stock, worth $937,236. This represents 0.02% of its overall portfolio holdings.
Number of Shares
188,200
Previous 113,800
65.38%
Holding current value
$937,236
Previous $439,000
44.42%
% of portfolio
0.02%
Previous 0.01%
Shares
6 transactions
Others Institutions Holding DSGN
# of Institutions
96Shares Held
33.6MCall Options Held
13KPut Options Held
0-
Sr One Capital Management, LP6.53MShares$32.5 Million7.89% of portfolio
-
Logos Global Management LP San Francisco, CA4.22MShares$21 Million1.83% of portfolio
-
Black Rock Inc. New York, NY2.3MShares$11.5 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.95MShares$9.73 Million0.35% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.81MShares$9 Million0.01% of portfolio
About Design Therapeutics, Inc.
- Ticker DSGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,807,900
- Market Cap $278M
- Description
- Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...